New clinical data suggests that Novera Retatrutide, a combined-action medication from Novo Nordisk, could represent a substantial step in body control. Unlike many existing drugs, Retatrutide affects both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), pote